Pharmacokinetics and pharmacodynamics of direct oral anticoagulants.
B HindleyG Y H LipA P McCloskeyPeter E PensonPublished in: Expert opinion on drug metabolism & toxicology (2023)
Patient-centered care necessitates a careful consideration of the pharmacokinetic and pharmacodynamic differences between DOACs, and how these relate to individual patient circumstances. Prescribers should be aware of the potential for pharmacokinetic drug interactions with DOACs which may influence prescribing decisions in patients with multiple comorbidities. In order to give an appropriate dose of DOAC drugs, accurate estimation of renal function using the Cockcroft-Gault formula using actual body weight is necessary. An increasing body of evidence supports the use of DOACs in patients who are obese, and this is becoming more routine in clinical practice.
Keyphrases
- patient reported
- direct oral anticoagulants
- venous thromboembolism
- atrial fibrillation
- body weight
- clinical practice
- primary care
- healthcare
- end stage renal disease
- palliative care
- adipose tissue
- type diabetes
- metabolic syndrome
- weight loss
- chronic kidney disease
- ejection fraction
- case report
- high resolution
- risk assessment
- pain management
- prognostic factors
- human milk
- peritoneal dialysis
- health insurance
- human health
- patient reported outcomes
- obese patients